Mircera

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
07-12-2023
Ciri produk Ciri produk (SPC)
07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
11-08-2023

Bahan aktif:

Methoxy polyethylene glycol-epoetin beta

Boleh didapati daripada:

Roche Registration GmbH

Kod ATC:

B03XA03

INN (Nama Antarabangsa):

methoxy polyethylene glycol-epoetin beta

Kumpulan terapeutik:

Antianemic preparations

Kawasan terapeutik:

Anemia; Kidney Failure, Chronic

Tanda-tanda terapeutik:

Treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients (see section 5.1).Treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (ESA) after their haemoglobin level was stabilised with the previous ESA (see section 5.1).

Ringkasan produk:

Revision: 29

Status kebenaran:

Authorised

Tarikh kebenaran:

2007-07-20

Risalah maklumat

                                53
B. PACKAGE LEAFLET
54
PACKAGE LEAFLET: INFORMATION FOR THE USER
MIRCERA
30 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
40 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
50 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
60 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
75 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
100 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
120 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
150 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
200 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
250 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
360 MICROGRAMS/0.6 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
methoxy polyethylene glycol-epoetin beta
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor. This includes any
possible side effects not listed
in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What MIRCERA is and what it is used for
2.
What you need to know before you use MIRCERA
3.
How to use MIRCERA
4.
Possible side effects
5.
How to store MIRCERA
6.
Contents of the pack and other information
1.
WHAT MIRCERA IS AND WHAT IT IS USED FOR
This medicine is prescribed to you because you have anaemia caused by
your chronic kidney disease
and associated with typical symptoms, such as tiredness, weakness and
shortness of breath. This
means that you have too few red blood cells and your haemoglobin level
is too low (your body’s
tissues might not receive enough oxygen).
MIRCERA is indicated to treat only the symptomatic an
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
MIRCERA 30 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 40 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 50 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 60 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 75 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 100 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 120 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 150 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 200 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 250 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 360 MICROGRAMS/0.6 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
MIRCERA 30 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
One pre-filled syringe contains 30 micrograms of methoxy polyethylene
glycol-epoetin beta* at a
concentration of 100 micrograms/ml
MIRCERA 40 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
One pre-filled syringe contains 40 micrograms of methoxy polyethylene
glycol-epoetin beta* at a
concentration of 133 micrograms/ml.
MIRCERA 50 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
One pre-filled syringe contains 50 micrograms of methoxy polyethylene
glycol-epoetin beta* at a
concentration of 167 micrograms/ml.
MIRCERA 60 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
One pre-filled syringe contains 60 micrograms of methoxy polyethylene
glycol-epoetin beta* at a
concentration of 200 micrograms/ml.
MIRCERA 75 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
One pre-filled syringe contains 75 micrograms of methoxy polyethylene
glycol-epoetin beta* at a
concentration of 250 micrograms/ml
MIRCERA 100 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
O
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 07-12-2023
Ciri produk Ciri produk Bulgaria 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 11-08-2023
Risalah maklumat Risalah maklumat Sepanyol 07-12-2023
Ciri produk Ciri produk Sepanyol 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 11-08-2023
Risalah maklumat Risalah maklumat Czech 07-12-2023
Ciri produk Ciri produk Czech 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Czech 11-08-2023
Risalah maklumat Risalah maklumat Denmark 07-12-2023
Ciri produk Ciri produk Denmark 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 11-08-2023
Risalah maklumat Risalah maklumat Jerman 07-12-2023
Ciri produk Ciri produk Jerman 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 11-08-2023
Risalah maklumat Risalah maklumat Estonia 07-12-2023
Ciri produk Ciri produk Estonia 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 11-08-2023
Risalah maklumat Risalah maklumat Greek 07-12-2023
Ciri produk Ciri produk Greek 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Greek 11-08-2023
Risalah maklumat Risalah maklumat Perancis 07-12-2023
Ciri produk Ciri produk Perancis 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 11-08-2023
Risalah maklumat Risalah maklumat Itali 07-12-2023
Ciri produk Ciri produk Itali 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Itali 11-08-2023
Risalah maklumat Risalah maklumat Latvia 07-12-2023
Ciri produk Ciri produk Latvia 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 11-08-2023
Risalah maklumat Risalah maklumat Lithuania 07-12-2023
Ciri produk Ciri produk Lithuania 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 11-08-2023
Risalah maklumat Risalah maklumat Hungary 07-12-2023
Ciri produk Ciri produk Hungary 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 11-08-2023
Risalah maklumat Risalah maklumat Malta 07-12-2023
Ciri produk Ciri produk Malta 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Malta 11-08-2023
Risalah maklumat Risalah maklumat Belanda 07-12-2023
Ciri produk Ciri produk Belanda 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 11-08-2023
Risalah maklumat Risalah maklumat Poland 07-12-2023
Ciri produk Ciri produk Poland 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Poland 11-08-2023
Risalah maklumat Risalah maklumat Portugis 07-12-2023
Ciri produk Ciri produk Portugis 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 11-08-2023
Risalah maklumat Risalah maklumat Romania 07-12-2023
Ciri produk Ciri produk Romania 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Romania 11-08-2023
Risalah maklumat Risalah maklumat Slovak 07-12-2023
Ciri produk Ciri produk Slovak 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 11-08-2023
Risalah maklumat Risalah maklumat Slovenia 07-12-2023
Ciri produk Ciri produk Slovenia 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 11-08-2023
Risalah maklumat Risalah maklumat Finland 07-12-2023
Ciri produk Ciri produk Finland 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Finland 11-08-2023
Risalah maklumat Risalah maklumat Sweden 07-12-2023
Ciri produk Ciri produk Sweden 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 11-08-2023
Risalah maklumat Risalah maklumat Norway 07-12-2023
Ciri produk Ciri produk Norway 07-12-2023
Risalah maklumat Risalah maklumat Iceland 07-12-2023
Ciri produk Ciri produk Iceland 07-12-2023
Risalah maklumat Risalah maklumat Croat 07-12-2023
Ciri produk Ciri produk Croat 07-12-2023
Laporan Penilaian Awam Laporan Penilaian Awam Croat 11-08-2023

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen